HER2 Breast Cancer
HER2 Breast Cancer
Advertisement
Kaitlyn KoskoHER2 Breast Cancer | May 9, 2025
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
Read More
Brandon TwyfordHER2 Breast Cancer | May 7, 2025
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
David Winchester, MDBreast Cancer News | May 10, 2025
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
David Winchester, MDBreast Cancer News | May 5, 2025
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 1, 2025
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 6, 2025
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Brandon TwyfordHER2 Breast Cancer | April 21, 2025
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Brandon TwyfordHER2 Breast Cancer | April 4, 2025
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Brianna GrahamHER2 Breast Cancer | April 3, 2025
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
Brianna GrahamHER2 Breast Cancer | April 2, 2025
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Brandon TwyfordHER2 Breast Cancer | April 2, 2025
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Jordana JampelHER2 Breast Cancer | March 25, 2025
TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy.
Aliya OmerHER2 Breast Cancer | March 25, 2025
Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer.
Rob DillardHER2 Breast Cancer | March 25, 2025
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
Jordana JampelHER2 Breast Cancer | March 25, 2025
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
Rob DillardTriple-Negative Breast Cancer | March 25, 2025
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
Advertisement
Advertisement
Latest News

May 9, 2025